Alzamend Neuro (ALZN) Income towards Parent Company (2020 - 2026)
Alzamend Neuro's (ALZN) quarterly Income towards Parent Company came in at -$2.9 million in Q2 2026, down 151.97% year-over-year from $5.5 million in Q2 2025, and down 30.56% quarter-over-quarter from -$2.2 million in Q1 2026.
Analysis
Alzamend Neuro (ALZN) Income towards Parent Company (2020 - 2026) Analysis & Trends
Alzamend Neuro has disclosed Income towards Parent Company across 7 years of filings, most recently posting -$2.9 million for Q2 2026.
- In Q2 2026, Income towards Parent Company fell 151.97% year-over-year to -$2.9 million; the TTM figure through Apr 2026 stood at -$8.8 million (down 92.04% YoY), while the FY2026 annual figure was -$8.8 million, down 94.3% from the prior year.
- Income towards Parent Company came in at -$2.9 million for Q2 2026 at Alzamend Neuro, down from -$2.2 million in the prior quarter.
- In the past five years, Income towards Parent Company ranged from a high of -$851529.0 in Q2 2024 to a low of -$5.4 million in Q1 2023.
- Average Income towards Parent Company over 5 years is -$2.5 million, with a median of -$2.7 million recorded in 2024.
- Year-over-year, Income towards Parent Company plunged 208.83% in 2022 and soared 74.24% in 2024.
- Over 5 years, Income towards Parent Company stood at -$3.1 million in 2022, then rose by 6.56% to -$2.9 million in 2023, then jumped by 51.3% to -$1.4 million in 2024, then grew by 29.29% to -$1.0 million in 2025, then plunged by 186.89% to -$2.9 million in 2026.
- Per Business Quant data, the three most recent Income towards Parent Company figures were -$2.9 million in Q2 2026, -$2.2 million in Q1 2026, and -$1.0 million in Q4 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Amgen | 206.86 Bn | 192.87 Bn | 7.24 Bn |
| 2 | Gilead Sciences | 179.52 Bn | 176.34 Bn | 6.22 Bn |
| 3 | Vertex Pharmaceuticals | 131.47 Bn | 123.62 Bn | 2.84 Bn |
| 4 | Regeneron Pharmaceuticals | 81.63 Bn | 73.63 Bn | 3.93 Bn |
| 5 | Argenx Se | 61.16 Bn | 55.98 Bn | 1.37 Bn |
| 6 | Moderna | 53.15 Bn | 48.02 Bn | 52.00 Mn |
| 7 | Alnylam Pharmaceuticals | 33.20 Bn | 29.89 Bn | 992.69 Mn |
| 8 | Biogen | 31.65 Bn | 30.37 Bn | 1.96 Bn |
| 9 | Roivant Sciences | 29.30 Bn | 29.30 Bn | 1.16 Mn |
| 10 | Alzamend Neuro | 5.57 Mn | 5.57 Mn | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Apr 30, 2026 | -2.87 Mn |
| Jan 31, 2026 | -2.20 Mn |
| Oct 31, 2025 | -1.00 Mn |
| Jul 31, 2025 | -2.70 Mn |
| Apr 30, 2025 | -1.14 Mn |
| Jan 31, 2025 | -1.04 Mn |
| Oct 31, 2024 | -1.42 Mn |
| Jul 31, 2024 | -974,411.00 |
| Apr 30, 2024 | -851,529.00 |
| Jan 31, 2024 | -2.66 Mn |
| Oct 31, 2023 | -2.91 Mn |
| Jul 31, 2023 | -3.53 Mn |
| Apr 30, 2023 | -3.31 Mn |
| Jan 31, 2023 | -5.43 Mn |
| Oct 31, 2022 | -3.11 Mn |
| Jul 31, 2022 | -3.04 Mn |
| Apr 30, 2022 | -3.87 Mn |
| Jan 31, 2022 | -2.57 Mn |
| Oct 31, 2021 | -3.60 Mn |
| Jul 31, 2021 | -2.32 Mn |